Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
about
Where Failure Is Not an Option -Personalized Medicine in AstronautsEvidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.AJG series: molecular biology for clinicians.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Proton pump inhibitor step-down therapy for GERD: a multi-center study in JapanPharmacogenomics of proton pump inhibitors.Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesCYP2C19 polymorphism and proton pump inhibitors.Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Pharmacogenetics-based new therapeutic concepts.Review article: the patient with gastro-oesophageal reflux disease--lifestyle advice and medication.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsSystematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in JapanCYP2C19 genotype and the PPIs--focus on rabeprazole.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Clinical application of pharmacogenetics in gastrointestinal diseases.PhRMA white paper on ADME pharmacogenomics.Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor TherapyEffects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy.A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD.Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Rabeprazole for the treatment of acid-related disorders.Refractory gastroesophageal reflux disease.A review of pharmacogenetics of adverse drug reactions in elderly people.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma CellsCharacteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom ReseTwice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration.
P2860
Q28550427-A27AF305-BABA-4A91-93F4-F81FC2181585Q30249468-6E48E666-54AF-4DC1-B08F-F3CB3ADC2F36Q33984210-91B9047D-DFCE-45AD-8D11-9DAD511AFE41Q34583603-BF938EAC-D075-4A7C-842D-0F47DD04CBC1Q34756783-7F1D8614-EBAE-4F9C-BB33-82439C634F29Q35689146-7F8FD5D0-732D-40AE-BD4C-3A743ED362BFQ35826075-0AA6300F-3981-43AC-810E-AAFB2D88EF2BQ35831792-35EF41C3-6CED-48D2-AFF3-DEAE28B24E90Q35868527-41B27864-93E3-4DDA-9AFC-A430DDD594E5Q35923954-923DF625-D2B4-47EF-B4FA-02105D4E6AB1Q35956177-10298A77-1FD7-4692-949D-9E9056F7471AQ35970051-4581B82A-70C3-4515-862E-38A54D9BCDD1Q35987201-87DB281F-101B-4B7C-BF82-A9C614FC1BB7Q36191254-EFDE2242-49DE-4F9E-AF1F-5EE083C0BA0AQ36265354-51FEBC62-5FF4-4742-9C93-EABCE278B3BCQ36344158-DC8EA20C-E260-4889-B529-DCC81E4E51ACQ36441521-387A34F4-565F-4D0D-B18B-FE542FED813BQ36613862-9BBEA7A6-3AB4-42BA-A896-CB9F3DECABC8Q37182212-9C8B04AC-BB74-4FAE-8F32-D550C38189A1Q37190537-B8301A7A-CACA-4477-AA01-998B17AC608FQ37726472-F5D496C0-0ABC-419B-8C54-2419C83FDAF2Q37834142-D2D44692-D95A-498A-8D69-DF78C4A9D066Q37959240-27F3EAED-87AD-4532-B27B-1EA80EAEDAEAQ37981892-404BCC51-8D20-4A85-AC58-4E74013FA9CDQ38032920-4EAB0DDE-F23E-46CE-8A81-A56C8394EBC6Q38038691-F8531887-9E03-4FD1-8C8D-3DBF39342E08Q38074868-6E6B30F4-6196-483C-97E0-17BA76B3D0E1Q38085220-7E5F8838-51DD-4468-8B95-62372EECACF3Q38196383-48EEC7CF-328C-441C-88C7-6261D17F2158Q38219028-F6D8BFE8-A235-4FB5-8BA7-A4F8191E361CQ38727019-DB989CBC-EB46-4AC1-A1EC-175355649B25Q38861693-0E42CCB7-1182-43C9-ABA7-B78B965DE170Q39115196-9ADCA9CD-B413-40C5-8E90-D7F63A6B317BQ39115202-930D2687-B2F2-4BB3-AA8E-BD5F2887AEF7Q39260588-394BEC6E-B109-47B7-928A-97568AF5A6D4Q39420822-38E76A38-E863-434F-B7B9-6D36729E136FQ39496600-C3E118D2-FA28-446F-8B47-E1D95734604FQ39496624-DE1907F0-C514-4D20-B038-533ACA6039C1Q40345111-239A5B75-6595-4A22-BEAD-53EA28E43CAAQ43042883-AA1BD75E-33E8-4405-A573-15891C5840F0
P2860
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@en
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@nl
type
label
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@en
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@nl
prefLabel
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@en
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@nl
P2093
P356
P1476
Effect of cytochrome P4502C19 ...... eflux disease by lansoprazole.
@en
P2093
Fumitoshi Watanabe
Hajime Futami
Hiroyuki Hanai
Ken Takeuchi
Kyoichi Ohashi
Masami Yamada
Masayoshi Kajimura
Naohito Shirai
Satoru Honda
Shigekazu Takayanagi
P304
P356
10.1067/MCP.2002.127637
P407
P577
2002-10-01T00:00:00Z